Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who had received the BNT162b2 (Pfizer/BioNTech) booster dose vs individuals with only two shots. 

¿Vale la pena la 3ª dosis contra el COVID-19 para todas las edades?

After the initial promising results of the mRNA COVID-19 vaccine booster dose given to +60 men and women, Israel decided to gradually extend the vaccination scheme to younger people who had received the second dose at least 5 months earlier. 

They gathered data from more than 4.5 million 16-year-olds or older who had received the second shot at least 5 months earlier. 

They carried out two analyses: on primary analysis, they looked at confirmed COVID-19, severe illness and death rates of people who had received the third dose at least 12 days earlier (booster group) against those with a conventional 2 shot scheme. They also did a secondary analysis for people receiving the booster shot between 3 to 7 days earlier (early post booster group).  

Confirmed case rate was lower for the booster group vs those receiving two shots by a factor of approximately 10. Confirmed cases were fewer in the booster group than in the early post-booster group. 


Read also: Pfizer Booster Dose Efficacy against Omicron.


Rates of severe illness in both analyses resulted lower for the booster group by a factor of nearly 20. This factor resulted higher for the elderly (over 20 for the +60 population vs. 3.7 for those between 40 and 59 years of age)

Conclusion

Across all ages, the confirmed or severe COVID-19 case rates resulted significantly lower among people receiving the booster shot vs people receiving the conventional 2 shot scheme. 

nejmoa2115926

Original Title: Protection against Covid-19 by BNT162b2 Booster across Age Groups.

Reference: Yinon M. Bar-On et al. N Engl J Med. 2021 Dec 23;385(26):2421-2430. doi: 10.1056/NEJMoa2115926. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and,...

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300...

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow...

Are Antithrombotics Necessary in Outpatients after COVID-19?

According to this recent study (soon to be published in JAMA), antithrombotic therapy has no clinical benefits for outpatients with stable symptoms of COVID-19.  Both...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...